http://www.caprostate.ca Prostate Health, Exam and Surgery Help and Resources Thu, 26 Aug 2010 07:04:50 +0000 http://backend.userland.com/rss092 en The latest people to object to the recent decision by the Centers for Medicare & Medicaid Services to open a National Coverage Analysis of the Provenge prostate cancer vaccine happen to be two US Senators. John Kerry and Arlen Specter, Democrats from Massachusetts and Pennsylvania, respectively, wrote an Aug. 20 ... http://www.caprostate.ca/uncategorized/senators-ask-why-medicare-is-reviewing-provenge This study involved two groups of HIV-1 infected men from the Netherlands: 29 who have sex with men, and 25 heterosexual men. The rationale for examining HIV-1 infected men for XMRV was that “they have a higher chance of contracting sexually transmitted pathogens than non-HIV-1 infected men”. For 39 men ... http://www.caprostate.ca/uncategorized/xmrv-not-detected-in-seminal-plasma Research showed a 69% boost to testosterone – the male sex hormone by being in sunlight. In America as winter begins, there is a dip noticed in both supply of Vitamin D and testosterone which continues till March.  So it is important to get enough sun if you want to ... http://www.caprostate.ca/uncategorized/sex-vitamin-scream-cream Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Ila Singh On episode #94 of the podcast This Week in Virology, Vincent, Alan, and Rich speak with Ila Singh about the new human retrovirus XMRV, and how her laboratory is studying its association with prostate cancer and chronic fatigue syndrome. Download TWiV #94 (56 ... http://www.caprostate.ca/uncategorized/twiv-94-xmrv-with-dr-ila-singh In a sharply worded letter to the Centers for Medicare & Medicaid Services, the American Society of Clinical Oncology takes the federal agency to task for conducting a coverage review of the Provenge prostate cancer vaccine. You may recall that CMS unexpectedly disclosed plans for a National Coverage Analysis in ... http://www.caprostate.ca/uncategorized/oncologists-criticizes-cms-for-provenge-review Given the intense interest in the Provenge prostate cancer vaccine, Wall Street is closely tracking the launch of the controversial Dendreon product, which was recently launched at a price tag of $93,000 a patient and is also the subject of a coverage review by the Centers for Medicare & Medicaid ... http://www.caprostate.ca/uncategorized/provenge-launch-appears-on-track-analyst Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double from nearly $4 billion in 2009 to $8.4 billion in 2019 in the ... http://www.caprostate.ca/uncategorized/the-launch-and-uptake-of-nine-emerging-therapies-will-drive-the-prostate-cancer-drug-market-to-more-than-double-to-8-4-billion-in-2019 Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in ... http://www.caprostate.ca/uncategorized/researchers-block-pathway-that-performs-key-function-in-end-stage-prostate-cancer Researchers at the USC Norris Comprehensive Cancer Center have received a $12 million National Cancer Institute (NCI) grant to lead a multi-institution international project aimed at identifying new biological pathways critical to the development and potential treatment of prostate cancer… Original post by Cancer Commentary and software by Elliott Back http://www.caprostate.ca/uncategorized/usc-leads-international-program-aimed-at-identifying-prostate-cancer-risk CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications… Original post by Cancer Commentary and software by Elliott Back http://www.caprostate.ca/uncategorized/cytrx-announces-substantial-progress-with-its-bafetinib-clinical-trials-program